| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0140-6736(92)93086-3 |
| P698 | PubMed publication ID | 1357461 |
| P2093 | author name string | M C Camargo | |
| C T Sacchi | |||
| B A Perkins | |||
| J C de Moraes | |||
| I M Landgraf | |||
| H A Barbosa | |||
| H de G Vasconcelos | |||
| N T Hidalgo | |||
| V L Gattas | |||
| P433 | issue | 8827 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Brazil | Q155 |
| vaccine | Q134808 | ||
| meningococcal vaccine | Q6817090 | ||
| P304 | page(s) | 1074-1078 | |
| P577 | publication date | 1992-10-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil | |
| P478 | volume | 340 |
| Q38132262 | A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn? |
| Q35949585 | A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial |
| Q79195144 | Active immunization against serogroup B Neisseria meningitidis |
| Q33975799 | Active immunization in the United States: developments over the past decade |
| Q36313869 | Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis. |
| Q38040527 | Advances with vaccination against Neisseria meningitidis |
| Q35689237 | Affinity-purified human immunoglobulin G that binds a lacto-N-neotetraose-dependent lipooligosaccharide structure is bactericidal for serogroup B Neisseria meningitidis. |
| Q80033881 | An effective serogroup B meningococcal vaccine |
| Q84729221 | An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups |
| Q34118124 | Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine |
| Q35224881 | Antibody responses to the capsular polysaccharide of Neisseria meningitidis serogroup B in patients with meningococcal disease |
| Q39777023 | Antibody specificities and effect of meningococcal carriage in icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine |
| Q39852648 | Approach to the Discovery, Development, and Evaluation of a Novel Neisseria meningitidis Serogroup B Vaccine |
| Q31806487 | Auto-transporter A protein of Neisseria meningitidis: a potent CD4+ T-cell and B-cell stimulating antigen detected by expression cloning |
| Q40508650 | Bacterial meningitis: mechanisms of disease and therapy |
| Q37492987 | Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease |
| Q37126987 | Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin |
| Q37994540 | Bexsero: a multicomponent vaccine for prevention of meningococcal disease. |
| Q30150784 | Can Neisseria lactamica antigens provide an effective vaccine to prevent meningococcal disease? |
| Q33867356 | Cellular immune responses to Neisseria meningitidis in children |
| Q34328514 | Cerebrospinal fluid |
| Q37503243 | Challenges and progress in the development of a serogroup B meningococcal vaccine |
| Q35998399 | Characterisation of the Immunomodulatory Effects of Meningococcal Opa Proteins on Human Peripheral Blood Mononuclear Cells and CD4+ T Cells. |
| Q36407498 | Characterization of invasive Neisseria meningitidis from Atlantic Canada, 2009 to 2013: With special reference to the nonpolysaccharide vaccine targets (PorA, factor H binding protein, Neisseria heparin-binding antigen and Neisseria adhesin A). |
| Q42000280 | Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination |
| Q47994063 | Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. |
| Q33704817 | Clonal distribution of disease-associated and healthy carrier isolates of Neisseria meningitidis between 1983 and 2005 in Cuba |
| Q46280467 | Commentary: Impact of meningococcal group B OMV vaccines, beyond their brief |
| Q34975624 | Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac |
| Q44473025 | Comparison of PorA VR types and porA promoter sequence from Neisseria meningitidis B isolated from non-immunised children and vaccine failures immunised with a serogroup B outer membrane protein vaccine |
| Q33591509 | Conjugated polysaccharide vaccines |
| Q34189137 | Conjugates and reverse vaccinology to eliminate bacterial meningitis |
| Q35436549 | Conjugates of synthetic cyclic peptides elicit bactericidal antibodies against a conformational epitope on a class 1 outer membrane protein of Neisseria meningitidis |
| Q34516060 | Construction of Opa-positive and Opa-negative strains of Neisseria meningitidis to evaluate a novel meningococcal vaccine |
| Q50116274 | Cross-protection induced by VA-MENGOC-BC® vaccine. |
| Q36642138 | Current status of meningococcal group B vaccine candidates: capsular or noncapsular? |
| Q89615572 | Deletion of major porins from meningococcal outer membrane vesicle vaccines enhances reactivity against heterologous serogroup B Neisseria meningitidis strains |
| Q84588187 | Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine |
| Q92769435 | Development and validation of a monocyte activation test for the control/safety testing of an OMV-based meningococcal B vaccine |
| Q34623334 | Development of vaccines against meningococcal disease |
| Q41099240 | Developments in childhood immunization |
| Q39781095 | Differential capacities of outer membrane proteins from Neisseria meningitidis B to prime the murine immune system after vaccination |
| Q33969625 | Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team. |
| Q40796063 | Effect of adjuvant composition on immune response to a multiple antigen peptide (MAP) containing a protective epitope from Neisseria meningitidis class 1 porin. |
| Q73700042 | Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine |
| Q81551035 | Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine in toddlers and school children |
| Q38640035 | Emerging clinical experience with vaccines against group B meningococcal disease. |
| Q73566962 | Enzyme linked immunosorbent assay (ELISA) for the detection of serum antibodies to the inner core lipopolysaccharide of Neisseria meningitidis group B |
| Q43954820 | Epidemiology of meningococcal disease in the city of Rio de Janeiro: changes after vaccination against B and C serogroups |
| Q37272815 | Epidemiology of pathogenic Neisseria meningitidis serogroup B serosubtypes in Malta: implications for introducing PorA based vaccines. |
| Q35533300 | Evaluation of recombinant transferrin-binding protein B variants from Neisseria meningitidis for their ability to induce cross-reactive and bactericidal antibodies against a genetically diverse collection of serogroup B strains |
| Q35806559 | FetA Antibodies Induced by an Outer Membrane Vesicle Vaccine Derived from a Serogroup B Meningococcal Isolate with Constitutive FetA Expression |
| Q38829564 | Fighting Neisseria meningitidis: past and current vaccination strategies |
| Q83852253 | From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak |
| Q34932489 | Functional activity of antibodies against the recombinant OpaJ protein from Neisseria meningitidis. |
| Q35946901 | Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines |
| Q40907011 | Functional assays for evaluation of serogroup B meningococcal structures as mediators of human opsonophagocytosis |
| Q80380471 | Generation of long-lived plasma cells to serogroup B Neisseria meningitidis after murine immunisation with an outer membrane protein vaccine |
| Q37798011 | Genetic shifts ofNeisseria meningitidisserogroup B antigens and the quest for a broadly cross-protective vaccine |
| Q38099207 | Genome-based bacterial vaccines: current state and future outlook. |
| Q44677055 | Global epidemiology of meningococcal disease. |
| Q38011311 | History of meningococcal vaccines and their serological correlates of protection |
| Q36094265 | Hospital-based surveillance of meningococcal meningitis in Salvador, Brazil |
| Q64228475 | Human Immune Responses and the Natural History of Infection |
| Q33867340 | Humoral immune responses to Neisseria meningitidis in children |
| Q30720717 | Identification and characterization of TspA, a major CD4(+) T-cell- and B-cell-stimulating Neisseria-specific antigen |
| Q24548670 | Immune response induction and new effector mechanisms possibly involved in protection conferred by the Cuban anti-meningococcal BC vaccine |
| Q34541047 | Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy |
| Q33756300 | Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial |
| Q34530695 | Immune responses in humans and animals to meningococcal transferrin-binding proteins: implications for vaccine design |
| Q36153379 | Immunisation of premature infants. |
| Q36898523 | Immunization with Vibrio cholerae outer membrane vesicles induces protective immunity in mice. |
| Q34007787 | Immunization with recombinant Opc outer membrane protein from Neisseria meningitidis: influence of sequence variation and levels of expression on the bactericidal immune response against meningococci |
| Q34127607 | Immunization with the recombinant PorB outer membrane protein induces a bactericidal immune response against Neisseria meningitidis. |
| Q53068514 | Immuno-proteomic analysis of human immune responses to experimental Neisseria meningitidis outer membrane vesicle vaccines identifies potential cross-reactive antigens. |
| Q43683511 | Immunogenicity and bactericidal activity in mice of an outer membrane protein vesicle vaccine against Neisseria meningitidis serogroup A disease |
| Q52032915 | Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. |
| Q73318541 | Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age |
| Q35635880 | Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents |
| Q34116994 | Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine |
| Q24548847 | Immunogenicity of intranasally administered meningococcal native outer membrane vesicles in mice |
| Q78036099 | Immunogenicity of various presentation forms of PorA outer membrane protein of Neisseria meningitidis in mice |
| Q36313603 | Immunogenicity, reactogenicity, and safety of a P1.7b,4 strain-specific serogroup B meningococcal vaccine given to preteens. |
| Q40642936 | Improving the immunogenicity of a trivalent Neisseria meningitidis native outer membrane vesicle vaccine by genetic modification |
| Q34221093 | In silico studies of outer membrane of Neisseria meningitidis por a: its expression and immunogenic properties |
| Q44012673 | Incidence and prognosis of meningitis due to Haemophilus influenzae, Streptococcus pneumoniae and Neisseria meningitidis in Sweden |
| Q72392463 | Infectious diseases |
| Q41640346 | Influence of disease burden, public perception, and other factors on new vaccine development, implementation, and continued use. |
| Q40502872 | Intranasal delivery of group B meningococcal native outer membrane vesicle vaccine induces local mucosal and serum bactericidal antibody responses in rabbits |
| Q35942903 | Invasive serogroup B Neisseria meningitidis in Quebec, Canada, 2003 to 2010: persistence of the ST-269 clone since it first emerged in 2003. |
| Q34214301 | Keeping the meningococcus out of the media. |
| Q72377468 | Meningitis |
| Q44495758 | Meningococcal Disease: The Organism, Clinical Presentation, and Worldwide Epidemiology |
| Q44393343 | Meningococcal disease caused by Neisseria meningitidis serogroup B serotype 4 in São Paulo, Brazil, 1990 to 1996. |
| Q33799641 | Meningococcal disease in healthcare workers. Vaccine is available in Latin America |
| Q38052545 | Meningococcal disease: changes in epidemiology and prevention |
| Q57707264 | Meningococcal genomics: two steps forward, one step back |
| Q35643952 | Meningococcal immunology |
| Q36241437 | Meningococcal infections at the start of the 21st century. |
| Q36530211 | Meningococcal serogroup W135 in the African meningitis belt: epidemiology, immunity and vaccines |
| Q38011312 | Meningococcal vaccine development--from glycoconjugates against MenACWY to proteins against MenB--potential for broad protection against meningococcal disease |
| Q80511370 | Meningococcal vaccines |
| Q34218569 | Meningococcal vaccines |
| Q37524027 | Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. |
| Q40864279 | Meningococcal vaccines. Current status and future possibilities |
| Q34318603 | Molecular techniques for the investigation of meningococcal disease epidemiology. |
| Q37290114 | Mucosal vaccination against bacterial respiratory infections |
| Q100511663 | Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates |
| Q43666330 | Multivalent liposome-based vaccines containing different serosubtypes of PorA protein induce cross-protective bactericidal immune responses against Neisseria meningitidis. |
| Q39113964 | Naturally-occurring human serum antibodies to inner core lipopolysaccharide epitopes of Neisseria meningitidis protect against invasive meningococcal disease caused by isolates displaying homologous inner core structures |
| Q37478314 | Neisseria lactamica antigens complexed with a novel cationic adjuvant |
| Q37932528 | Neisseria meningitidis B vaccines. |
| Q53252856 | Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. |
| Q40273227 | Neisseria meningitidis nasopharyngeal carriage during the Hajj: A cohort study evaluating the need for ciprofloxacin prophylaxis |
| Q77957593 | Neisseria meningitidis serogroup B outer membrane vesicle vaccine in adults with occupational risk for meningococcal disease |
| Q28298589 | Neisseria meningitidis: vaccines and vaccine candidates |
| Q46582106 | Neisseria vaccines 2007. |
| Q42413093 | Neisserial outer membrane vesicles bind the coinhibitory receptor carcinoembryonic antigen-related cellular adhesion molecule 1 and suppress CD4+ T lymphocyte function. |
| Q37878480 | New frontiers in meningococcal vaccines |
| Q37690815 | New versus old meningococcal group B vaccines: how the new ones may benefit infants & toddlers |
| Q39215403 | Novel approaches to Neisseria meningitidis vaccine design. |
| Q52955673 | On the controversy about the efficacy of the antimeningococcal B vaccine: methodological pitfalls |
| Q50942520 | On the neisserial vaccine quest: Neisseria Vaccines 2007. |
| Q37825922 | Opa proteins and CEACAMs: pathways of immune engagement for pathogenic Neisseria |
| Q35887397 | Oral administration of recombinant Neisseria meningitidis PorA genetically fused to H. pylori HpaA antigen increases antibody levels in mouse serum, suggesting that PorA behaves as a putative adjuvant |
| Q38325374 | Outbreaks of meningococcal B infection and the 4CMenB vaccine: historical and future perspectives |
| Q43441551 | Outer membrane vesicles of Neisseria lactamica as a potential mucosal adjuvant. |
| Q46560177 | Passive protection in the infant rat protection assay by sera taken before and after vaccination of teenagers with serogroup B meningococcal outer membrane vesicle vaccines |
| Q34720380 | Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine |
| Q30227840 | Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles |
| Q82790203 | Phase I study of a Neisseria meningitidis liposomal vaccine containing purified outer membrane proteins and detoxified lipooligosaccharide |
| Q42776796 | Population coverage analysis of T-Cell epitopes of Neisseria meningitidis serogroup B from Iron acquisition proteins for vaccine design |
| Q35913669 | PorA variable antigenic regions VR1, VR2, and VR3 of Neisseria meningitidis serogroups B and C isolated in Brazil from 1999 to 2004 |
| Q36973781 | Postgenomics of Neisseria meningitidis for vaccines development |
| Q37455163 | Postgenomics of Neisseria meningitidis: an update. |
| Q38068953 | Preclinical evaluation of MenB vaccines: prerequisites for clinical development |
| Q39219241 | Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease |
| Q35947795 | Predicted Strain Coverage of a New Meningococcal Multicomponent Vaccine (4CMenB) in Spain: Analysis of the Differences with Other European Countries |
| Q24676339 | Preventative strategies on meningococcal disease |
| Q34214286 | Primary care provision of specialist services. |
| Q34983894 | Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis |
| Q33724705 | Prophylaxis of bacterial meningitis |
| Q33999628 | Proposed standardization of Neisseria meningitidis PorA variable-region typing nomenclature. |
| Q24537338 | Prospects for vaccine prevention of meningococcal infection |
| Q34355276 | Prospects offered by genome studies for combating meningococcal disease by vaccination |
| Q30230636 | Proteomic analysis of Neisseria lactamica and N eisseria meningitidis outer membrane vesicle vaccine antigens. |
| Q42232579 | Proteomic analysis of outer membranes and vesicles from wild-type serogroup B Neisseria meningitidis and a lipopolysaccharide-deficient mutant. |
| Q42231387 | Quantification by LC-MS(E) of outer membrane vesicle proteins of the Bexsero® vaccine |
| Q35143299 | Rational antibacterial vaccine design through genomic technologies |
| Q34006346 | Recombinant Neisseria meningitidis transferrin binding protein A protects against experimental meningococcal infection |
| Q37880078 | Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles |
| Q34955474 | Recombinant protein truncation strategy for inducing bactericidal antibodies to the macrophage infectivity potentiator protein of Neisseria meningitidis and circumventing potential cross-reactivity with human FK506-binding proteins |
| Q37362174 | Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease |
| Q78840806 | Restored functional immunogenicity of purified meningococcal PorA by incorporation into liposomes |
| Q35040848 | Reverse vaccinology: a genome-based approach for vaccine development |
| Q33646965 | Review of meningococcal group B vaccines |
| Q37095094 | Ribotyping as an additional molecular marker for studying Neisseria meningitidis serogroup B epidemic strains |
| Q73028966 | Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers |
| Q37683962 | Serogroup B meningococcal vaccines-an unfinished story |
| Q35648260 | Serologic correlates of protection for evaluating the response to meningococcal vaccines |
| Q33973163 | Serosubtypes and PorA types of Neisseria meningitidis serogroup B isolated in Brazil during 1997--1998: overview and implications for vaccine development |
| Q35224023 | Serotypes and subtypes of Neisseria meningitidis: results of an international study comparing sensitivities and specificities of monoclonal antibodies. |
| Q74841476 | Serum bactericidal activity and isotype distribution of antibodies in toddlers and schoolchildren after vaccination with RIVM hexavalent PorA vesicle vaccine |
| Q37371372 | Short-term and long-term antibody response by mice after immunization against Neisseria meningitidis B or diphtheria toxoid |
| Q30159962 | Solution structure of the immunodominant domain of protective antigen GNA1870 of Neisseria meningitidis |
| Q39573174 | Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with an outer membrane vaccine. |
| Q35506194 | Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine |
| Q44740509 | Stability of mono- and trivalent meningococcal outer membrane vesicle vaccines |
| Q28344521 | Standardization of Neisseria meningitidis serogroup B colorimetric serum bactericidal assay |
| Q33946678 | T-cell-stimulating protein A elicits immune responses during meningococcal carriage and human disease. |
| Q34214294 | Telemedicine: 'communication' by any other name? |
| Q44087691 | The effect of subcapsular meningococcal B + C vaccine on the prognosis of patients with meningococcal disease |
| Q37706585 | The epidemiology of meningococcal disease and the impact of vaccines |
| Q36593391 | The epidemiology of meningococcal disease in Latin America 1945-2010: an unpredictable and changing landscape. |
| Q59243317 | The infant rat model adapted to evaluate human sera for protective immunity to group B meningococci1Presented in part at The Tenth International Pathogenic Neisseria Conference, Baltimore, MD, USA, September 8–13, 1996.1 |
| Q34712881 | The meningococcus tamed? |
| Q38677309 | The next chapter for group B meningococcal vaccines |
| Q34150340 | Three doses of an experimental detoxified L3-derived lipooligosaccharide meningococcal vaccine offer good safety but low immunogenicity in healthy young adults |
| Q36327065 | Towards an improved serogroup B Neisseria meningitidis vaccine |
| Q33889550 | Update on Haemophilus influenzae serotype b and meningococcal vaccines |
| Q33812435 | Update on meningococcal disease with emphasis on pathogenesis and clinical management |
| Q43862409 | Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years |
| Q33610780 | Use of transformation to construct antigenic hybrids of the class 1 outer membrane protein in Neisseria meningitidis |
| Q26779489 | Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysis |
| Q43496518 | Vaccination of patients deficient in a late complement component with tetravalent meningococcal capsular polysaccharide vaccine |
| Q37274707 | Vaccine development against Neisseria meningitidis |
| Q34460367 | Vaccine prevention of meningococcal disease, coming soon? |
| Q30771493 | Vaccines against meningococcal disease: current and future technologies |
| Q53090874 | [Assessing the effectiveness of vaccination programs]. |
| Q44774028 | [Meningococcus B serosubtypes causing invasive disease in Cantabria [Spain] and agreement with the Cuban vaccine strain]. |
Search more.